Company Information

Dynogen Team Overview
Management Biographies
Board of Directors
Scientific Advisory Board

News Articles

Mass High Tech - Startups smell success with gastro treatments

Press Releases

For additional company information, please contact Mark Boshar at Dynogen via phone at 781-839-5114 or via e-mail at .

Dynogen Presents Results of Its Positive Phase 2a IBS-c Study with DDP733
May 20, 2008

Dynogen Presents Results of Its Positive Phase 2a IBS-c Study with DDP733
May 20, 2008

Dynogen Presents Results of Its Positive Phase 2 IBS-d Study with DDP225
May 20, 2008

Dynogen to Present Positive Clinical Data for DDP225 and DDP733 at Digestive Disease Week 2008 Conference
April 30, 2008

Dynogen Pharmaceuticals and Apex Bioventures Mutually Terminate Merger Agreement
April 16, 2008

Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive Merger Agreement
February 6, 2008

Dynogen Expands DDP225 Patent Estate
January 16, 2008

Dynogen Announces Positive Results in Phase 2 IBS-d Study
December 17, 2007

Dynogen's Prokinetic Drug, DDP733, Enters Phase 2B for Irritable Bowel Syndrome with Constipation
November 8, 2007

Dynogen's Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1B Study
October 15, 2007

Dynogen Reports Positive Results in Phase 1B GERD Study
June 7, 2007

Dynogen to Receive Two Key European Patents for DDP733
April 17 , 2007

Dynogen Reports Positive Results in Phase 2 IBS-c Study
February 13, 2007

Dynogen Awarded U.S. Patent for Use of DDP225 in Overactive Bladder
October 4, 2006

Dynogen Initiates Phase Ib Trial of DDP733 in Gastroesophageal Reflux Disease (GERD)
September 13, 2006

Dynogen Research Operation Acquired by Astellas Pharma Inc.
March 1, 2006

Dynogen's Portfolio Strengthened with New U.S. Patent for DDP733
January 17, 2006

Dynogen Initiates Phase II Trial of DDP225 for Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome
October 17, 2005

Dynogen Initiates Phase II Trial of DDP733 for Treatment of Patients with Constipation-Predominant Irritable Bowel Syndrome
September 28, 2005

Dynogen Appoints Dr. Suhail Nurbhai as Vice President, Clinical Development
September 8, 2005

Dynogen Awarded Broad U.S. Patent Relating to Treatment of Lower Urinary Tract Disorders
January 24, 2005

Dynogen Acquires Exclusive Rights to a Clinical-Stage Prokinetic Drug Candidate for Gastrointestinal Disorders
November 4, 2004

Dynogen Licenses Compounds from Newron for Genitourinary and Gastrointestinal Disorders
October 12, 2004

Dynogen Appoints Jan H. Egberts, M.D. as Chief Operating Officer
August 12, 2004

Dynogen Secures $50 Million Series B Financing to Advance its Pipeline of Genitourinary and Gastrointestinal Development Programs
April 19, 2004

Dynogen Pharmaceuticals, Inc. Enters into Overactive Bladder Collaboration with Johnson and Johnson Pharmaceutical Research and Development
January 5, 2004

Dynogen Pharmaceuticals, Inc. Enters into Agreement with Mitsubishi Pharma for Irritable Bowel Syndrome Compound
December 22, 2003

Evotech OAI to Support Dynogen Pharmaceuticals in the Discovery and Development of Novel Pharmaceuticals
January 30, 2003

Dynogen Pharmaceuticals, Inc. Raises $13.25 Million in Initial Financing
November 13, 2002